Sign in

CIK 0001636282

  • Large accelerated filer

Spyre Therapeutics, Inc.

Sign in to watch
Ticker
SYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464312787
Phone
+1 617-651-5940
Business address
221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
Former names
Aeglea BioTherapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$12,349,597
in 6 filings, $12.3M under 10b5-1 plans

Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2016-05-17 Hebel Henry VP, Product Development Grant or award · Employee Stock Option (right to buy) +43,000 43,000
2016-05-17 GEORGIOU GEORGE Director Grant or award · Director Stock Option (right to buy) +24,000 24,000
2016-05-17 Cox Russell J. Director Grant or award · Director Stock Option (right to buy) +10,000 10,000
2016-04-12 LILLY ELI & CO 10% owner Conversion +2,010,924 2,068,543
2016-04-12 LILLY ELI & CO 10% owner Conversion +2,010,924 2,068,543
2016-04-12 LILLY ELI & CO 10% owner Purchase +500,000 $10.00 $5.0M 2,568,543
2016-04-12 LILLY ELI & CO 10% owner Conversion · Series A Preferred Stock −890,476 0
2016-04-12 LILLY ELI & CO 10% owner Conversion · Series B Preferred Stock −1,120,448 0
2016-04-12 York Charles N II Chief Financial Officer and VP Conversion +1,324 8,828
2016-04-12 York Charles N II Chief Financial Officer and VP Conversion +11,560 11,560
2016-04-12 York Charles N II Chief Financial Officer and VP Conversion · Series B Preferred Stock −1,324 0
2016-04-12 York Charles N II Chief Financial Officer and VP Conversion · Series A Preferred Stock −9,523 0
2016-04-12 York Charles N II Chief Financial Officer and VP Conversion · Series B Preferred Stock −2,037 0
2016-04-12 TYLER JOSEPH E VP, Manufacturing Conversion +31,260 42,428
2016-04-12 TYLER JOSEPH E VP, Manufacturing Conversion · Series A Preferred Stock −22,857 0
2016-04-12 TYLER JOSEPH E VP, Manufacturing Conversion · Series B Preferred Stock −8,403 0
2016-04-12 Rowlinson Scott W VP, Research Conversion +11,204 11,204
2016-04-12 Rowlinson Scott W VP, Research Conversion · Series B Preferred Stock −11,204 0
2016-04-12 Quinn Anthony Director Purchase +10,000 $10.00 $100K 10,000
2016-04-12 Novartis Bioventures Ltd 10% owner Conversion +2,010,924 2,010,924

Page 20 of 21 · 407 trades